Latest Panitumumab Stories
QIAGEN N.V. (NASDAQ: QGEN) (FRANKFURT: QIA) today announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (CRC) patients.
Bristol-Myers Squibb and ImClone have presented five year data demonstrating an improved survival rate for head and neck cancer patients when receiving Erbitux and radiotherapy.
TrimGen Corporation, a U.S. molecular diagnostic company focused on developing advanced genetic tests, today announced the release of Mutector II(TM) KRAS kit.
MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc.
Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer.
ALISO VIEJO, Calif., July 1 /PRNewswire-FirstCall/ -- Clarient, Inc.
Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan.
Amgen (NASDAQ: AMGN) today announced updated results from the "STEPP" (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer (mCRC) patients receiving epidermal growth factor receptor (EGFr) therapy.
IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix)...
Merck KGaA has submitted an application to the European Medicines Agency to broaden the use of the targeted therapy Erbitux to include first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.